NervGen Pharma (TSE:NGEN) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NervGen Pharma’s Chief Medical Officer will present a clinical trial update for NVG-291, a therapeutic peptide designed to repair nervous system damage, at the International Spinal Cord Society Annual Meeting. The presentation will discuss the trial’s design and early results, which aim to demonstrate NVG-291’s potential in promoting neural repair in spinal cord injuries (SCI).
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.